PRESS-NEWS.org - Press Release Distribution
PRESS RELEASES DISTRIBUTION

Study captures sharp uptake in use of new weight loss and glucose-lowering medications

Mass General Brigham researchers found that by December 2023, more than 1 in 3 of the medications being started for type 2 diabetes treatment were GLP-1RA-based medications, such as semaglutide or tirzepatide

2025-04-14
(Press-News.org) When it comes to managing weight loss and type 2 diabetes with medications, research shows that it’s out with the old and in with the new. Investigators from Mass General Brigham looked at claims data from nearly 2 million people between 2021 and 2023 and their findings highlight a shifting landscape for weight loss and glucose managing medications. Those changes include a sharp climb in the use of newly approved medications, especially tirzepatide, which is sold under the brand name Mounjaro for diabetes treatment and Zepbound for weight loss. The use of medications previously common in the treatment of type 2 diabetes, including metformin, sulfonylureas, and insulin, decreased. Results are published in Annals of Internal Medicine.

“Taken together, these findings highlight the rapidly shifting landscape of prescribing patterns for glucose-lowering and weight-lowering medications,” said lead author John W. Ostrominski, MD, of the Cardiovascular Division, Division of Endocrinology, Diabetes and Hypertension, and Division of Pharmacoepidemiology and Pharmacoeconomics at Brigham and Women’s Hospital, a founding member of the Mass General Brigham healthcare system. “These changing trends likely reflect the combination of new evidence, increased awareness and prioritization of obesity treatment, and changing guidance for how to help patients manage these conditions.”

The study, which was funded by the National Institute of Diabetes and Digestive and Kidney Diseases, examined claims data among people with commercial insurance. The researchers report that in January 2021, approximately half of the weight-lowering medications initiated by people without diabetes were GLP-1RA-based medications such as semaglutide and tirzepatide. By December 2023, this percentage increased to nearly 90%, with tirzepatide being the most commonly started (31%). Use of other weight loss medications, such as phentermine and liraglutide, declined.

 

Among people with type 2 diabetes, 13% started GLP-1RA-based medications in January 2021. That rate rose to 35% by December 2023. Metformin, the most commonly started glucose-lowering medication in January 2021 (30%), declined to 19% by December 2023.

When the authors compared the immediate post-approval uptake of tirzepatide to other medications recently approved for type 2 diabetes or obesity, they found that the rise in tirzepatide’s use was steeper and more sustained.

“We saw a sharp uptake of tirzepatide after regulatory approval—these kinds of trends are important for patients, clinicians, researchers, and policymakers to be aware of,” said Ostrominski. “The rapidly expanding uptake of tirzepatide and GLP-1RA underscores the need for clinicians to become more familiar with their use, for researchers to improve understanding of their long-term effects, and for health policy that promotes sustained access and affordability.”

The researchers note several limitations to the work, including that it is uncertain whether the findings from commercially insured U.S. adults are generalizable to other populations and countries.

“Importantly, we don’t yet have long-term data from outcomes trials for tirzepatide as we do for GLP-1RA, but preliminary data are reassuring,” said Ostrominski. “In the future, data comparing the benefits of tirzepatide versus semaglutide for glycemic control, obesity management, and cardiovascular outcomes will help us have more informed conversations with patients about choosing the medication that’s right for them.”

Authorship: In addition to Ostrominski, Mass General Brigham authors include Janinne Ortega-Montie,l Helen Tesfaye, Caroline Alix, Elyse DiCesare, Elisabetta Patorno, Sara J. Cromer, Deborah J. Wexler, and Julie M. Paik.

Disclosures: Disclosure forms are available with the article online.

Funding: National Institute of Diabetes and Digestive and Kidney Diseases.

Paper cited: Ostrominski JW et al. “Trends in Utilization of Glucose- and Weight-Lowering Medications After Tirzepatide Approval in the United States” Annals of Internal Medicine DOI: 10.7326/ANNALS-24-02870

 

###

About Mass General Brigham

Mass General Brigham is an integrated academic health care system, uniting great minds to solve the hardest problems in medicine for our communities and the world. Mass General Brigham connects a full continuum of care across a system of academic medical centers, community and specialty hospitals, a health insurance plan, physician networks, community health centers, home care, and long-term care services. Mass General Brigham is a nonprofit organization committed to patient care, research, teaching, and service to the community. In addition, Mass General Brigham is one of the nation’s leading biomedical research organizations with several Harvard Medical School teaching hospitals. For more information, please visit massgeneralbrigham.org.

END



ELSE PRESS RELEASES FROM THIS DATE:

Van Andel Institute to recognize Dr. J. Timothy Greenamyre with 2025 Jay Van Andel Award for Outstanding Achievement in Parkinson’s Disease Research

2025-04-14
GRAND RAPIDS, Mich. (April 14, 2025) — Van Andel Institute has named renowned physician-scientist J. Timothy Greenamyre, M.D., Ph.D., as recipient of its 2025 Jay Van Andel Award for Outstanding Achievement in Parkinson’s Disease Research.   The award will be presented during Grand Challenges in Parkinson’s Disease, VAI’s flagship annual Parkinson’s disease symposium, Sept. 9–10, 2025. Greenamyre’s pioneering research into the interactions between genes and the environment has vastly improved our understanding of Parkinson’s development and progression. He has published more than 200 articles detailing ...

One firearm injury was treated every 30 minutes in emergency departments in a study of 10 jurisdictions

2025-04-14
Embargoed for release until 5:00 p.m. ET on Monday 14 April 2025    Follow @Annalsofim on X, Facebook, Instagram, Threads, and LinkedIn         Below please find summaries of new articles that will be published in the next issue of Annals of Internal Medicine. The summaries are not intended to substitute for the full articles as a source of information. This information is under strict embargo and by taking it into possession, media representatives are committing to the terms of the embargo not only on their own behalf, but also on behalf of the organization they represent.    ----------------------------       1. ...

The gut health benefits of sauerkraut

The gut health benefits of sauerkraut
2025-04-14
Is sauerkraut more than just a tangy topping? A new University of California, Davis, study published in Applied and Environmental Microbiology suggests that the fermented cabbage could help protect your gut, which is an essential part of overall health, supporting digestion and protecting against illness. Authors Maria Marco, professor with the Department of Food Science and Technology, and Lei Wei, a postdoctoral researcher in Marco’s lab, looked at what happens during fermentation — specifically, how the metabolites ...

Children’s Hospital of Philadelphia researchers chart natural history of patients with SCN8A-related disorders

2025-04-14
Philadelphia, April 14, 2024 – Researchers from the Epilepsy Neurogenetics Initiative (ENGIN) at Children’s Hospital of Philadelphia (CHOP) have completed a comprehensive natural history study of SCN8A-related disorders, which represent a spectrum of neurological symptoms. The study, using retrospective clinical information analyzed through novel data analysis methods, revealed a range of seizure types and neurodevelopmental features, and identifies potential targets for future clinical trials. The findings were published online on April 14, 2025, in Neurology®, the medical journal ...

Archaeologists measured and compared the size of 50,000 ancient houses to learn about the history of inequality -- they found that it’s not inevitable

Archaeologists measured and compared the size of 50,000 ancient houses to learn about the history of inequality -- they found that it’s not inevitable
2025-04-14
We’re living in a period where the gap between rich and poor is dramatic, and it’s continuing to widen. But inequality is nothing new. In a new study published in the journal PNAS, researchers compared house size distributions from more than 1,000 sites around the world, covering the last 10,000 years. They found that while inequality is widespread throughout human history, it’s not inevitable, nor is it expressed to the same degree at every place and time. “This paper is part of ...

Peptide imitation is the sincerest form of plant flattery

Peptide imitation is the sincerest form of plant flattery
2025-04-14
LA JOLLA (April 18, 2025)—Industrial farming practices often deplete the soil of important nutrients and minerals, leaving farmers to rely on artificial fertilizers to support plant growth. In fact, fertilizer use has more than quadrupled since the 1960s, but this comes with serious consequences. Fertilizer production consumes massive amounts of energy, and its use pollutes the water, air, and land. Plant biologists at the Salk Institute are proposing a new solution to help kick this unsustainable fertilizer habit. In a new study, the researchers identified ...

Archaeologists discover historical link between inequality and sustainability

2025-04-14
EMBARGOED UNTIL 15.00 US ET (20.00 BST) ON MONDAY 14 APRIL 2025 The study lead by Professor Dan Lawrence, of Durham University in the UK, found that across ten millennia, more unequal distributions of wealth correlated with longer-term human settlement.  However, the team are keen to stress that one factor is not causally dependent on the other, giving hope that humankind’s survival is not linked to ever increasing inequality. The research is part of a Special Feature of the Proceedings of the National Academy of Sciences (PNAS), entitled Global Dynamics of Wealth Inequality. Sustainability is defined by the ...

Researchers develop an LSD analogue with potential for treating schizophrenia

Researchers develop an LSD analogue with potential for treating schizophrenia
2025-04-14
University of California, Davis researchers have developed a new, neuroplasticity-promoting drug closely related to LSD that harnesses the psychedelic’s therapeutic power with reduced hallucinogenic potential. The research, published in Proceedings of the National Academy of Sciences, highlights the new drug’s potential as a treatment option for conditions like schizophrenia, where psychedelics are not prescribed for safety reasons. The compound also may be useful for treating other neuropsychiatric ...

How does our brain regulate generosity?

How does our brain regulate generosity?
2025-04-14
Are there areas of the brain, which regulate prosocial, altruistic behaviour? Together with colleagues from the universities in Lausanne, Utrecht and Cape Town, researchers from Heinrich Heine University Düsseldorf (HHU) have studied a very special group of patients and established that the “basolateral amygdala” (part of the limbic system) plays an important role in this. In the scientific journal Proceedings of the National Academy of Sciences (PNAS), they describe that this region calibrates social behaviour. Prosocial ...

New study reveals wealth inequality’s deep roots in human prehistory

2025-04-14
PULLMAN, Wash. — Wealth inequality began shaping human societies more than 10,000 years ago, long before the rise of ancient empires or the invention of writing. That’s according to a new study led by Washington State University archaeologist Tim Kohler that challenges traditional views that disparities in wealth emerged suddenly with large civilizations like Egypt or Mesopotamia. The research is part of a special issue of the Proceedings of the National Academy of Sciences, co-edited by Kohler and Amy Bogaard, an archaeologist at Oxford University in England. Drawing on data from over 47,000 residential ...

LAST 30 PRESS RELEASES:

Father’s mental health can impact children for years

Scientists can tell healthy and cancerous cells apart by how they move

Male athletes need higher BMI to define overweight or obesity

How thoughts influence what the eyes see

Unlocking the genetic basis of adaptive evolution: study reveals complex chromosomal rearrangements in a stick insect

Research Spotlight: Using artificial intelligence to reveal the neural dynamics of human conversation

Could opioid laws help curb domestic violence? New USF research says yes

NPS Applied Math Professor Wei Kang named 2025 SIAM Fellow

Scientists identify agent of transformation in protein blobs that morph from liquid to solid

Throwing a ‘spanner in the works’ of our cells’ machinery could help fight cancer, fatty liver disease… and hair loss

Research identifies key enzyme target to fight deadly brain cancers

New study unveils volcanic history and clues to ancient life on Mars

Monell Center study identifies GLP-1 therapies as a possible treatment for rare genetic disorder Bardet-Biedl syndrome

Scientists probe the mystery of Titan’s missing deltas

Q&A: What makes an ‘accidental dictator’ in the workplace?

Lehigh University water scientist Arup K. SenGupta honored with ASCE Freese Award and Lecture

Study highlights gaps in firearm suicide prevention among women

People with medical debt five times more likely to not receive mental health care treatment

Hydronidone for the treatment of liver fibrosis associated with chronic hepatitis B

Rise in claim denial rates for cancer-related advanced genetic testing

Legalizing youth-friendly cannabis edibles and extracts and adolescent cannabis use

Medical debt and forgone mental health care due to cost among adults

Colder temperatures increase gastroenteritis risk in Rohingya refugee camps

Acyclovir-induced nephrotoxicity: Protective potential of N-acetylcysteine

Inhibition of cyclooxygenase-2 upregulates the nuclear factor erythroid 2-related factor 2 signaling pathway to mitigate hepatocyte ferroptosis in chronic liver injury

AERA announces winners of the 2025 Palmer O. Johnson Memorial Award

Mapping minds: The neural fingerprint of team flow dynamics

Patients support AI as radiologist backup in screening mammography

AACR: MD Anderson’s John Weinstein elected Fellow of the AACR Academy

Existing drug has potential for immune paralysis

[Press-News.org] Study captures sharp uptake in use of new weight loss and glucose-lowering medications
Mass General Brigham researchers found that by December 2023, more than 1 in 3 of the medications being started for type 2 diabetes treatment were GLP-1RA-based medications, such as semaglutide or tirzepatide